This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muraro, R. Articles by Schlom, J. Search for Related Content PubMed PubMed Citation Articles by Muraro, R. Articles by Schlom, J.

Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen

Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH[R. M., M. K., D. W., D. J. P., D. C., A. T., J. W. G., J. F. S., A. M., J. S.], and Office of Biologics, National Center for Drugs and Biologics, Food and Drug Administration [P. N.], Bethesda, MD 20892

Monoclonal antibody (MAb) B72.3 was generated using a membraneenriched fraction of a human mammary carcinoma biopsy. It has demonstrated reactivity to the majority of human adenocarcinomas including colorectal, gastric, pancreatic, ovarian, endometrial, mammary, and non-small cell lung cancer and no or weak reactivity to normal adult tissues, with the exception of secretory endometrium. The B72.3-reactive antigen, termed tumor-associated glycoprotein (TAG)-72, has been purified and used as an immunogen to generate B72.3 second generation MAbs. Since the source of purified TAG-72 was a human colon cancer (CC) xenograft, these MAbs have been given a CC designation. Twenty-eight CC MAbs, all immunoglobulin Gs, have been generated and shown to be reactive with TAG-72 and via both radioimmunoassay and immunohistochemical analyses show differential reactivity to carcinoma versus normal adult tissue biopsies. Nine CC MAbs (CC11, 15, 29, 30, 40, 46, 49, 83, and 92) were selected for further characterization. As a result of analyses using direct-binding radioimmunoassay to a range of human carcinomas, Western blotting, live cell surface binding assays, five liquid competition radioimmunoassays, and K_a measurements, all nine CC MAbs could be distinguished from each other and from B72.3. The K_a of B72.3 was determined to be 2.54 x 10⁹ M^-1; all the CC MAbs demonstrated higher K_as with MAbs CC92, 49, and 83 having K_as of 14.26, 16.18, and 27.72 x 10⁹ M^-1, respectively. These studies thus demonstrate that one or more of the anti-TAG-72 CC MAbs may be more efficient than B72.3, or useful in combination with B72.3, toward the further study of human carcinoma cell population and the diagnostic and therapeutic procedures presently utilizing MAb B72.3.

¹ To whom requests for reprints should be addressed at Laboratory of Tumor Immunology and Biology, National Cancer Institute, Building 10, Room 8B07, Bethesda, MD 20892.

Received 2/24/88. Revised 5/12/88. Accepted 5/20/88.

This article has been cited by other articles:

				M. Roberge, M. Estabrook, J. Basler, R. Chin, P. Gualfetti, A. Liu, S. B. Wong, M. H. Rashid, T. Graycar, L. Babe, et al. Construction and optimization of a CC49-Based scFv-{beta}-lactamase fusion protein for ADEPT Protein Eng. Des. Sel., April 1, 2006; 19(4): 141 - 145. [Abstract] [Full Text] [PDF]

				S. O. Yoon, T. S. Lee, S. J. Kim, M. H. Jang, Y. J. Kang, J. H. Park, K.-S. Kim, H. S. Lee, C. J. Ryu, N. R. Gonzales, et al. Construction, Affinity Maturation, and Biological Characterization of an Anti-tumor-associated Glycoprotein-72 Humanized Antibody J. Biol. Chem., March 17, 2006; 281(11): 6985 - 6992. [Abstract] [Full Text] [PDF]

				S. M. Glaser, I. E. Hughes, J. R. Hopp, K. Hathaway, D. Perret, and M. E. Reff Novel Antibody Hinge Regions for Efficient Production of CH2 Domain-deleted Antibodies J. Biol. Chem., December 16, 2005; 280(50): 41494 - 41503. [Abstract] [Full Text] [PDF]

				S. Vallabhajosula, I. Kuji, K. A. Hamacher, S. Konishi, L. Kostakoglu, P. A. Kothari, M. I. Milowski, D. M. Nanus, N. H. Bander, and S. J. Goldsmith Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu? J. Nucl. Med., April 1, 2005; 46(4): 634 - 641. [Abstract] [Full Text] [PDF]

				S. S. Graves, E. Dearstyne, Y. Lin, Y. Zuo, J. Sanderson, J. Schultz, A. Pantalias, D. Gray, D. Axworthy, H. M. Jones, et al. Combination Therapy with Pretarget CC49 Radioimmunotherapy and Gemcitabine Prolongs Tumor Doubling Time in a Murine Xenograft Model of Colon Cancer More Effectively Than Either Monotherapy Clin. Cancer Res., September 1, 2003; 9(10): 3712 - 3721. [Abstract] [Full Text] [PDF]

				J. Svitel, A. Balbo, R. A. Mariuzza, N. R. Gonzales, and P. Schuck Combined Affinity and Rate Constant Distributions of Ligand Populations from Experimental Surface Binding Kinetics and Equilibria Biophys. J., June 1, 2003; 84(6): 4062 - 4077. [Abstract] [Full Text] [PDF]

				F. J. Kelly, C. R. Miller, D. J. Buchsbaum, J. Gomez-Navarro, M. N. Barnes, R. D. Alvarez, and D. T. Curiel Selectivity of TAG-72-targeted Adenovirus Gene Transfer to Primary Ovarian Carcinoma Cells versus Autologous Mesothelial Cells in Vitro Clin. Cancer Res., November 1, 2000; 6(11): 4323 - 4333. [Abstract] [Full Text] [PDF]

				M. Tempero, P. Leichner, J. Baranowska-Kortylewicz, K. Harrison, S. Augustine, J. Schlom, J. Anderson, J. Wisecarver, and D. Colcher High-Dose Therapy with 90Yttrium-labeled Monoclonal Antibody CC49: A Phase I Trial Clin. Cancer Res., August 1, 2000; 6(8): 3095 - 3102. [Abstract] [Full Text]

				M. Tamura, D. E. Milenic, M. Iwahashi, E. Padlan, J. Schlom, and S. V. S. Kashmiri Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only J. Immunol., February 1, 2000; 164(3): 1432 - 1441. [Abstract] [Full Text] [PDF]

				G. Pavlinkova, B. J. M. Booth, S. K. Batra, and D. Colcher Radioimmunotherapy of Human Colon Cancer Xenografts Using a Dimeric Single-Chain Fv Antibody Construct Clin. Cancer Res., September 1, 1999; 5(9): 2613 - 2619. [Abstract] [Full Text] [PDF]

				P. V. Beum, J. Singh, M. Burdick, M. A. Hollingsworth, and P.-W. Cheng Expression of Core 2 beta -1,6-N-Acetylglucosaminyltransferase in a Human Pancreatic Cancer Cell Line Results in Altered Expression of MUC1 Tumor-associated Epitopes J. Biol. Chem., August 27, 1999; 274(35): 24641 - 24648. [Abstract] [Full Text] [PDF]

				D. COLCHER, G. PAVLINKOVA, G. BERESFORD, B. J.M. BOOTH, and S. K. BATRA Single-Chain Antibodies in Pancreatic Cancer Ann. N.Y. Acad. Sci., June 30, 1999; 880(1): 263 - 280. [Abstract] [Full Text] [PDF]